Biogen (BIIB) Operating Leases (2018 - 2026)

Biogen's Operating Leases history runs 9 years deep, the most recent figure standing at $273.4 million for Q1 2026.

• In Q1 2026, Operating Leases fell 15.46% year-over-year to $273.4 million; the TTM figure through Mar 2026 stood at $273.4 million (down 15.46% YoY), while the FY2025 annual figure was $290.4 million, down 31.0% from the prior year.
• Operating Leases was $273.4 million for Q1 2026 at Biogen, down from $290.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $490.3 million in Q4 2023 to a low of $273.4 million in Q1 2026.
• Historically, Operating Leases has averaged $351.6 million across 5 years, with a median of $327.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Leases soared 30.21% in 2022, then tumbled 31.0% in 2025.
• A 5-year view of Operating Leases shows it stood at $430.2 million in 2022, then advanced by 13.97% to $490.3 million in 2023, then dropped by 14.15% to $420.9 million in 2024, then sank by 31.0% to $290.4 million in 2025, then slipped by 5.85% to $273.4 million in 2026.
• The last three Operating Leases figures came in at $273.4 million (Q1 2026), $290.4 million (Q4 2025), and $305.0 million (Q3 2025), per Business Quant data.